Medication info
IdalDIPIN 40/10 mg (Azilsartan Medoxomil, Amlodipine Besylate)

IdalDIPIN 40/10 mg (Azilsartan Medoxomil, Amlodipine Besylate)

Prescription medicationTabletOral
Ingredient · strength
Potassium Azilsartan Medoxomil›42.68mg / 1 tabletAmlodipine Besylate›13.889mg / 1 tablet
Manufacturer / importer
Celltrion, Inc.
Appearance
Bright red oval film-coated tablet
Packaging
30 tablets / PTP [(15 tablets * 2 ea)]
Approval status
Active

MFDS item code 202502799 · Approved 2025.10.29 · Insurance code 623800380

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
▪ Adults Take 1 tablet once daily with water, with or without food. It is recommended to take the tablet at the same time each day (e.g., in the morning), if possible. 40/5 mg: For patients whose blood pressure is not adequately controlled with azilsartan medoxomil 40 mg or amlodipine 5 mg monotherapy. 40/10 mg: For patients whose blood pressure is not adequately controlled with azilsartan medoxomil 40 mg or amlodipine 10 mg monotherapy, or with this drug 40/5 mg. 80/5 mg: For patients whose blood pressure is not adequately controlled with azilsartan medoxomil 80 mg monotherapy. 80/10 mg: For patients whose blood pressure is not adequately controlled with azilsartan medoxomil 80 mg or this drug 80/5 mg. Patients taking each of the individual drugs concomitantly may switch to this drug (a combination product containing the same amount of each active ingredient) for convenience. ▪ Elderly patients Dosage adjustment is generally not necessary; however, for patients 75 years of age or older, an initial dose of azilsartan medoxomil 20 mg should be considered, so starting treatment with this drug is not recommended. ▪ Patients with renal impairment Dosage adjustment is not necessary in patients with mild or moderate renal impairment. ▪ Patients with hepatic impairment For patients with mild to moderate hepatic impairment, an initial dose of azilsartan medoxomil 20 mg should be considered, so starting treatment with this drug is not recommended. ▪ Patients with intravascular volume depletion For patients who are salt-depleted or may have reduced effective circulating volume (e.g., those with vomiting or diarrhea, or those receiving high doses of diuretics), an initial dose of azilsartan medoxomil 20mg should be considered, so starting treatment with this drug is not recommended.
Child dose
▪ Children The safety and efficacy of this drug have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Celltrion, Inc.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used to effectively control blood pressure in patients with essential hypertension whose blood pressure is not adequately controlled with monotherapy of azilsartan medoxomil or amlodipine.

How to take

Adult dose

▪ Adults Take 1 tablet once daily with water, with or without food. It is recommended to take the tablet at the same time each day (e.g., in the morning), if possible. 40/5 mg: For patients whose blood pressure is not adequately controlled with azilsartan medoxomil 40 mg or amlodipine 5 mg monotherapy. 40/10 mg: For patients whose blood pressure is not adequately controlled with azilsartan medoxomil 40 mg or amlodipine 10 mg monotherapy, or with this drug 40/5 mg. 80/5 mg: For patients whose blood pressure is not adequately controlled with azilsartan medoxomil 80 mg monotherapy. 80/10 mg: For patients whose blood pressure is not adequately controlled with azilsartan medoxomil 80 mg or this drug 80/5 mg. Patients taking each of the individual drugs concomitantly may switch to this drug (a combination product containing the same amount of each active ingredient) for convenience. ▪ Elderly patients Dosage adjustment is generally not necessary; however, for patients 75 years of age or older, an initial dose of azilsartan medoxomil 20 mg should be considered, so starting treatment with this drug is not recommended. ▪ Patients with renal impairment Dosage adjustment is not necessary in patients with mild or moderate renal impairment. ▪ Patients with hepatic impairment For patients with mild to moderate hepatic impairment, an initial dose of azilsartan medoxomil 20 mg should be considered, so starting treatment with this drug is not recommended. ▪ Patients with intravascular volume depletion For patients who are salt-depleted or may have reduced effective circulating volume (e.g., those with vomiting or diarrhea, or those receiving high doses of diuretics), an initial dose of azilsartan medoxomil 20mg should be considered, so starting treatment with this drug is not recommended.

Child dose

▪ Children The safety and efficacy of this drug have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the second and third trimester of pregnancy. Therefore, it should be discontinued immediately if pregnancy is confirmed. Patients who are allergic to this medication or have hypersensitivity to its components should not take it. Patients with diabetes or severe renal disease should avoid taking this medication with certain drugs, and it is also recommended that those with severe hepatic impairment do not take it. This medication should not be used in patients with severe aortic stenosis or in shock. Caution should be exercised for patients with congestive heart failure, severe renal impairment, renal artery stenosis, or similar conditions dependent on the renin-angiotensin-aldosterone system, as there is a risk of acute hypotension or renal failure. This medication may cause a sudden drop in blood pressure, so patients with reduced blood volume or low salt levels may experience hypotension, requiring condition adjustment before starting and monitoring by healthcare professionals. Patients with hyperkalemia or at risk of elevated serum potassium levels should have their potassium levels frequently checked when taking this medication. Patients with aortic stenosis, mitral stenosis, obstructive or hypertrophic cardiomyopathy, ischemic cardiomyopathy, cerebrovascular disease, heart failure, post-myocardial infarction patients, and elderly patients should be especially cautious when taking this medication. This medication may cause various side effects such as dizziness, headache, hypotension, peripheral edema, etc. If any unusual symptoms occur, consult immediately with medical personnel. For patients with impaired liver function, the half-life of this medication may be prolonged, requiring dose adjustment and caution. Due to blood pressure lowering effects, drowsiness or dizziness may occur while driving or operating machinery, so caution is advised. This medication may interact with other drugs, particularly lithium, non-steroidal anti-inflammatory drugs, potassium-sparing diuretics, and potassium supplements. Blood pressure, kidney function, and electrolyte levels should be monitored periodically while taking these medications together. Pregnant and nursing women should not take this medication, as it can be particularly dangerous to the fetus during pregnancy and must be discussed with healthcare professionals. Safety for children and adolescents under 18 years of age has not been established, so it is preferable not to use it. Elderly patients, especially those over 75, are at higher risk of hypotension and should start at a lower dose and be closely monitored. In case of overdose, hypotension, dizziness, and in severe cases, shock may occur, requiring immediate emergency treatment, and continuous monitoring of blood pressure and cardiac function is necessary even after discontinuation of the medication.

Side effects

  • Hyperkalemia
  • dizziness
  • headache
  • hypotension
  • glomerulonephritis
  • increased blood potassium
  • weakness
  • peripheral edema
  • peripheral swelling
  • diarrhea
Show 113 more
  • nausea
  • rash
  • pruritus
  • angioedema
  • muscle cramp
  • fatigue
  • increased blood creatine phosphokinase
  • increased blood creatinine
  • increased blood uric acid
  • nasopharyngitis
  • chest discomfort
  • syncope
  • pre-syncope
  • constipation
  • vomiting
  • foul breath
  • dyspnea
  • dyslipidemia
  • hypercholesterolemia
  • gout
  • arthralgia
  • myalgia
  • musculoskeletal stiffness
  • increased aspartate aminotransferase
  • urinary tract infection
  • upper respiratory infection
  • acute kidney injury
  • diabetic nephropathy
  • dermatitis
  • urticaria
  • hair loss
  • subdural hemorrhage
  • menstrual irregularities
  • worsening hypertension
  • chest pain
  • palpitations
  • flushing
  • fatigue
  • edema
  • tachycardia
  • vertigo
  • drowsiness
  • abdominal pain
  • nausea
  • weakness
  • lethargy
  • pain
  • weight gain
  • weight loss
  • vasculitis
  • tension increase
  • sensory loss
  • sensory disturbance
  • peripheral neuropathy
  • taste disturbance
  • tremor
  • extrapyramidal disorder
  • erectile dysfunction
  • gynecomastia
  • change in bowel habits
  • dry mouth
  • dyspepsia
  • gastritis
  • gingival hyperplasia
  • pancreatitis
  • hyperglycemia
  • arthralgia
  • low back pain
  • muscle cramps
  • myalgia
  • leukopenia
  • thrombocytopenia
  • insomnia
  • mood changes
  • cough
  • rhinitis
  • hyperhidrosis
  • purpura
  • skin discoloration
  • toxic epidermal necrolysis
  • tinnitus
  • visual disturbances
  • increased frequency of urination
  • urinary disturbances
  • nocturia
  • hepatitis
  • jaundice
  • elevated liver enzymes
  • pruritus
  • erythema multiforme
  • myocardial infarction
  • arrhythmia
  • chest pain
  • hypotension
  • sinoatrial block
  • atrioventricular block
  • abdominal discomfort
  • skin erythema
  • maculopapular rash
  • heaviness
  • warmth
  • reduced glucose tolerance
  • weakness
  • pulmonary edema
  • rapid blood pressure drop
  • shock
  • fainting
  • transient loss of consciousness
  • reduced kidney function
  • excessive peripheral vasodilation
  • reflex tachycardia
  • systemic hypotension
  • non-cardiogenic pulmonary edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to avoid exposure to air or moisture, at a temperature between 1 degree Celsius and 30 degrees Celsius. Storing it this way helps maintain the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

Bright red oval film-coated tablet

Package unit

30 tablets / PTP [(15 tablets * 2 ea)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.